


## Supplementary figures




Supplementary fig. S1 correlation analysis between somatostatin and GLP-1 output. Correlation analysis are based on average output each minute from somatostatin and GLP-1 during the perfusion of the proximal small intestine. A) Average output each minute from 1-100 min in C57BL/6JRj mice of somatostatin and GLP-1 output in perfusion experiments where glucose or glucose + SSTR2a was given (shown in Fig. 1A-D). GLP-1 average of n=8, SS based on n=5. B) Same as A, but for SSTR5a infusion, average of n=6 for both hormones (shown in fig 1 E-H). C) Average output each minute from 1-40 min in Sstr5-/- of GLP-1 and somatostatin n=5 for both hormones (shown in fig. 1 I-K). D) Same as C, but in Sstr-/- mice, n=5 for both hormones (shown in fig. 1 I-K).



Supplementary fig. S2. SSTr2a and SSTr5a decrease blood glucose *in vivo* in female mice and combining the antagonists in male mice further improves glucose tolerance. Female mice received vehicle (black), 4 mg/kg SSTR2a (red) or SSTR5a (blue) by sc injection 15 minutes before an oral glucose load. A) Plasma blood glucose levels (mmol/l), n=8. B) Plasma insulin levels (pmol/l), n=8. C) Total GLP-1 plasma levels (pmol/l), n=8. D) Male mice received vehicle (black), 4 mg/kg SSTR2a (red), SSTR5a (blue) or SSTR2a+ SSTR5a in combination (grey) by sc injection 15 minutes before an oral glucose load. D) Plasma blood glucose levels (mmol/l), n=12. E) Plasma insulin levels (pmol/l), n=12. Data are presented as mean ± SEM. Significance at specific time points was assessed by two-way ANOVA followed by Tukey post hoc analysis to correct for multiple testing.



**Supplementary fig. S3. Oral gavage of SSTR5a decrease blood glucose in a dose dependent manner.** Male mice received vehicle (black), 5 mg/kg SSTR5a (red) or 50 mg/kg SSTR5a (blue) by oral gavage 30 minutes before an oral glucose load. Data are presented as mean ± SEM, n=5-6. Statistical significance was based on iAUC from 0-120 min and tested by one-way ANOVA followed by the Tukey post hoc analysis to correct for multiple testing, \*p<0.05, \*\*\*p<0.001. The box plots show the median and 25th and 75th percentiles, and the whiskers represent the smallest and highest value.



**Supplementary fig. S4.** Sc injection of SSTr2a and SSTr5a lowers blood glucose in control mice but have no effect in DIO mice. Control and DIO mice received sc administration of vehicle (black), 8 mg/kg SSTr2a (red) or SSTr5a (blue) 15 min before oral glucose. A) Plasma blood glucose levels (mmol/l) in control mice, n=4 B) Plasma blood glucose levels (mmol/l) in DIO mice, n=5-6. Data are presented as means ± SEM.